SOURCE: Omni Bio Pharmaceutical
June 02, 2009 17:21 ET
Omni Bio Pharmaceutical, Inc. Completes Name Change and Announces Managerial Appointments and Position Changes
DENVER, CO--(Marketwire - June 2, 2009) - Omni Bio Pharmaceutical, Inc. ("OMNI") (OTCBB: AAFS) announces that it has consummated the previously announced name
change from Across America Financial Services, Inc. The Company is in
process of having a new ticker symbol assigned to more closely reflect its
name and will announce the new symbol once it becomes effective.
Omni also announced the appointment of Robert C. Ogden to the positions of
Chief Financial Officer, Secretary and Treasurer of both Omni and its
wholly owned subsidiary Omni Bio Operating, Inc. Mr. Ogden will be engaged
on a part-time basis and is expected to spend approximately 50% of his time
on Company related business.
Mr. Ogden brings 20 years of senior financial management experience in both
private and public companies. Since 2007, Mr. Ogden has been a financial
consultant providing services ranging from interim Vice President of
Finance of an IP telephony software company to SEC reporting and accounting
assistance for a multi-national, business process outsourcing services
company. From 2004 to 2007, Mr. Ogden served as Chief Financial Officer,
Treasurer and Secretary of SAN Holdings, Inc., a publicly traded data
storage solutions provider and software company, where he was responsible
for all administrative and finance functions. From 2000 to 2004, he was a
financial consultant, primarily providing financial controller and
financial reporting services for both private and public companies in a
variety of industries, including software, computer hardware and financial
services. From 1997 to 2000, he served as Vice President, Corporate
Controller and Chief Accounting Officer for TAVA Technologies, Inc., a
publicly held national systems integration and software company. He began
his career as a public accountant with PricewaterhouseCoopers. Mr. Ogden
holds a B.S. in Commerce from the University of Virginia and is a CPA.
Additionally, both Omni and Omni Bio Operating, Inc. appointed Edward C.
Larkin as Chief Operating Officer and Executive Vice President. Mr. Larkin
had served as Omni's interim Chief Financial Officer. He has been
associated with Omni and its predecessor, Apro Bio Pharmaceutical, Inc.,
since January 2007.
About Omni Bio Pharmaceutical, Inc.
Omni is the licensee of issued and pending patents from the University of
Colorado. Omni has been advancing broad-spectrum therapeutics targeting
bacterial and viral diseases, biohazards, diabetes and transplant rejection
since February 2006.
The Company's core technology is based on novel discoveries made at the
University of Colorado involving therapeutic agents already approved for
use in humans.
Regarding Forward-Looking Statements
Statements in this document regarding future financial, scientific or
operating results, future development programs, the development and
commercialization of new supplier, partner or customer contracts, the
commitment of suppliers and future opportunities for any of the companies
mentioned herein, and any other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not statements of
historical fact (including but not limited to statements containing the
words "will," "believes," "plans," "anticipates," "expects," "estimates,"
and similar expressions) should also be considered to be forward-looking
There are a number of important factors that could cause actual results or
events to differ materially from those indicated by such forward-looking
statements, including: variations in results of animal or human clinical
trials, engineering and material costs, development costs, the availability
of future financing on terms that are acceptable to any of the companies
mentioned herein, other general costs and expenses; the ability to retain
key personnel; the Company's ability to successfully execute its business
strategies; the levels and availability of government sponsored research
programs including possible funding from the Project Bio-Shield Act of 2004
and the Pandemic and All Hazards Act of 2006; lack of commercial revenues;
delays in the possible development of a commercial market for products due
to FDA restrictions or requirements to increase our levels of clinical
testing; our reliance on a limited number of suppliers for raw materials
used in products; shortages of raw materials; competitive conditions in the
industry; business cycles affecting the markets in which any of the
companies mentioned herein conducts business; and economic conditions
Additional risk factors may be found in the company's Form 8-K., filed
April 6, 2009 and in other documents filed by the Company with the U.S.
Securities and Exchange Commission.
Forward-looking statements are based on the beliefs, opinions and
expectations of the Company's management as of the date of this press
release, and the companies mentioned herein do not assume any obligation to
update their forward-looking statements if those beliefs, opinions,
expectations, or other circumstances should change.